Sequence diversity and functional characterization of the 5′-regulatory region of human CYP2C19

Pharmacogenetics

Volumn 13, Issue 4, 2003, Pages 199-206

  Arefayene, Million ^a   Skaar, Todd C ^a   Zhao, Xiaojiong ^a   Rae, James M ^c   Tanus Santos, Jose E ^a   Brinkmann, Ulrich ^b   Brehm, Ilka ^b   Salat, Ulrike ^b   Nguyen, Anne ^a   Desta, Zeruesenay ^a   Flockhart, David A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Epidauros Biotechnologie AG   (Germany)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

CYP2C19; Omeprazole; Polymorphism; Promoter; Rifampin; Sequence; Transcription factor

Indexed keywords

ANDROSTANE DERIVATIVE; CYTOCHROME P450 2C19; ESTROGEN RECEPTOR; GLUCOCORTICOID; LUCIFERASE; OMEPRAZOLE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PREGNANE X RECEPTOR; RIFAMPICIN; TRANSCRIPTION FACTOR;

5' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DNA SEQUENCE; DRUG TRANSFORMATION; GENE DELETION; GENE EXPRESSION; GENE INDUCTION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE;

AMINO ACID SEQUENCE; BASE SEQUENCE; BINDING SITES; DNA PRIMERS; HUMANS; LUCIFERASES; OMEPRAZOLE; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RECOMBINANT FUSION PROTEINS; REGULATORY SEQUENCES, NUCLEIC ACID; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; VARIATION (GENETICS);

EID: 0038561222     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200304000-00004     Document Type: Article

References (21)

1. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C family. Br J Clin Pharmacol 2001; 52:349-355.
2. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41:913-958.
3. Kupfer A, Desmond PV, Schenker S, Branch RA. Family study of a genetically determined deficiency of mephenytoin hydroxylation in man. Pharmacologist 1979; 21:173.
4. Andersson T, Holmberg J, Rohss K, Walan A. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole and pantoprazole. Br J Clin Pharmacol 1998; 45:369-375.
5. Andersson T, Cederberg C, Evardsson G, Heggelund A, Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 1990; 47:79-85.
6. Liddle C, Goodwin B. Regulation of hepatic drug metabolism: role of the nuclear receptors PXR and CAR. Semin Liver Dis 2002; 22:115-122.
7. Zhou HH, Anthony LB, Wood AJ, Wilkinson GR. Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol 1990; 30:471-475.
8. Feng HJ, Huang SL, Wang W, Zhou HH. The induction effect of rifampicin on activity of mephenytoin 4′-hydroxylase related to M1 mutation of CYP2C19 and gene dose. Br J Clin Pharmacol 1998; 45:27-29.
9. Runge D, Kohler C, Kostrubsky VE, Jager D, Lehmann T, Runge DM, et al. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes. Biochem Biophys Res Commun 2000; 273:333-341.
10. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 2001; 29:242-251.
11. Raucy JL, Mueller L, Duan K, Allen SW, Strom S, Lasker JM. Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. J Pharmacol Exp Ther 2002; 302:475-482.
12. Svensson US, Ashton M, Trinh NH, Bertilsson L, Dinh XH, Nguyen VH, et al. Artemisinin induces omeprazole metabolism in human beings. Clin Pharmacol Ther 1998; 64:160-167.
13. Mihara K, Svensson US, Tybring G, Hai TN, Bertilsson L, Ashton M. Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19. Fundam Clin Pharmacol 1999; 13:671-675.
14. Fuhr U. Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans. Clin Pharmacokinet 2000; 38:493-504.
15. Zelko I, Negishi M. Phenobarbital-elicited activation of nuclear receptor CAR in induction of cytochrome P450 genes. Biochem Biophys Res Commun 2000; 217:1-6.
16. Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991; 30:3247-3255.
17. Hashimoto H, Toide K, Kitamura R, Fukui M, Tagawa S, Itoh S, et al. Gene structure of CYP3A4, An adult-specific form of Cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem 1993; 218:585-595.
18. de Morais SM, Schweikl H, Blaisdell JA, Goldstein JA. Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. Biochem Biophys Res Commun 1993; 194:194-201.
19. Klose TS, Blaisdell JA, Goldstein JA. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol 1999; 13:289-295.
20. Xie W, Barwick JL, Simon CM, Pierce AM, Safe S, Blumberg B, et al. Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev 2000; 14:3014-3023.
21. Gerbal-Chaloin S, Daujat M, Pascussi JM, Pichard-Garcia L, Vilarem MJ, Maurel P. Transcriptional regulation of CYP2C9 gene: role of glucocorticoid receptor and constitutive androstane receptor. J Biol Chem 2002; 277:209-217.